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Introduction: Many patients with oncogene-driven non–small-cell 
lung cancer (NSCLC) treated with tyrosine kinase inhibitors expe-
rience limited sites of disease progression. This study investigated 
retrospectively the benefits of local ablative therapy (LAT) to central 
nervous system (CNS) and/or limited systemic disease progression 
and continuation of crizotinib or erlotinib in patients with metastatic 
ALK gene rearrangement (ALK+) or EGFR-mutant (EGFR-MT) 
NSCLC, respectively.
Methods: Patients with metastatic ALK+ NSCLC treated with crizo-
tinib (n = 38) and EGFR-MT NSCLC treated with erlotinib (n = 27) 
were identified at a single institution. Initial response to the respective 
kinase inhibitors, median progression-free survival (PFS1), and site of 
first progression were recorded. A subset of patients with either nonlep-
tomeningeal CNS and/or four sites or fewer of extra-CNS progression 
(oligoprogressive disease) suitable for LAT received either radiation or 
surgery to these sites and continued on the same tyrosine kinase inhibi-
tors. The subsequent median progression-free survival from the time 
of first progression (PFS2) and pattern of progression were recorded.
Results: Median progression-free survival in ALK+ patients on 
crizotinib was 9.0 months, and 13.8 months for EGFR-MT patients 
on erlotinib. Twenty-five of 51 patients (49%) who progressed were 
deemed suitable for local therapy (15 ALK+, 10 EGFR-MT; 24 with 
radiotherapy, one with surgery) and continuation of the same targeted 
therapy. Post-LAT, 19 of 25 patients progressed again, with median 
PFS2 of 6.2 months.
Discussion: Oncogene-addicted NSCLC with CNS and/or limited 
systemic disease progression (oligoprogressive disease) on relevant 
targeted therapies is often suitable for LAT and continuation of the 
targeted agent, and is associated with more than 6 months of addi-
tional disease control.
Key Words: EGFR-mutant non–small-cell lung cancer, anaplastic 
lymphoma kinase gene arrangement non–small-cell lung cancer, 
Radiation therapy, Oligoprogressive disease.
(J Thorac Oncol. 2012;7: 1807–1814)
Patients with metastatic non–small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rear-
rangements (ALK+) or epidermal growth factor receptor-
mutations (EGFR-MTs) have high response rates and long 
progression-free survival times when treated with crizotinib 
or EGFR tyrosine kinase inhibitors (TKIs), such as erlo-
tinib, respectively.1–6 However, progression inevitably occurs 
because of either inadequate central nervous system (CNS) 
penetration of the drug in some cases of CNS progression, 
or biological change in the tumor such as the development of 
new kinase domain mutations in the drug target or the devel-
opment of alternate oncogenic drivers.7–16
Although studies of many novel agents are ongoing, 
there are no currently approved targeted therapies specific 
for treatment of such patients upon progression. Although 
continuation of the TKI therapy by itself with no local 
therapy to slow the progression or continuation of the TKI 
in combination with chemotherapy have been advocated 
as options for these patients,17–20 the current standard 
therapeutic option at the time of progression is to treat the 
patient with cytotoxic chemotherapy alone. Local therapies, 
such as radiotherapy or surgery, have had little role outside 
symptom palliation in this setting. However, radiation therapy 
of isolated CNS progression in patients with EGFR-mutant 
NSCLC being treated with EGFR-TKIs and continued 
systemic administration of the TKI if there is no evidence 
of systemic progression has recently been described.21 Such 
an approach relies on the logic that CNS progression could 
reflect inadequate drug penetration rather than a change in the 
biology of the cancer. Therefore, the patient is unlikely to have 
developed systemic resistance to the drug and may be deriving 
significant ongoing benefit from its use.
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Building on this logic, the approach we describe here 
uses local therapies to ablate sites of oligoprogressive disease 
that occurs systemically, as well as in the CNS, and continu-
ing the same targeted therapy and is based on two underly-
ing hypotheses. First, given our increasing knowledge about 
the different mechanisms of acquired resistance to TKIs 
in EGFR-MT and ALK+ disease, we hypothesized that any 
biological change mediating acquired resistance occurs as 
a stochastic clonal event that favors survival in accordance 
with Darwinian evolutionary principles.14–16 Consequently, if 
treated with ablative therapy before widespread dissemination 
of the resistant clone, disease control may be prolonged until 
either a new event occurs or resistant clones that have dis-
seminated expand enough to become detectable. Second, we 
hypothesized that there is ongoing benefit from the targeted 
therapy in other sites of (nonprogressing) disease because of 
continuing suppression of sensitive clones that have not yet 
developed acquired resistance. Consistent with this, patients 
with EGFR-MT disease who progress often experience a dis-
ease flare when the EGFR-TKI is discontinued,22 and rechal-
lenge of these patients with the same EGFR-TKI after only 
a short time off therapy can lead to re-responses.23,24 In addi-
tion, treatment beyond progression of EGFR-MT NSCLC 
with an EGFR-TKI has been associated with improved overall 
survival, compared with those in whom the TKI was perma-
nently discontinued.25 Analogous benefits of the continuation 
of trastuzumab beyond progression have been well described 
in metastatic breast cancer.26–29
This study describes a single-institution experience of 
using local ablative therapy (LAT) and continuation of the 
same targeted therapy to treat ALK+ and EGFR-MT meta-
static NSCLC patients who progress either within the CNS 
and/or at limited systemic sites (oligoprogressive disease) 
while on crizotinib or erlotinib, respectively. In most cases we 
used stereotactic body radiation therapy (SBRT) as our LAT 
of choice. SBRT has previously been shown to be highly effec-
tive in achieving local control in a variety of organs, without 
significant toxicity.30–37
MATERIALS AND METHODS
Patients
Patients eligible for inclusion in this retrospective analy-
sis included all patients with histologically confirmed ALK+ or 
EGFR-MT metastatic NSCLC at the University of Colorado 
Cancer Center treated with crizotinib, or erlotinib between 
May 2005 and December 2011 with adequate follow-up data. 
Patients were identified through a query of the Colorado 
Molecular Correlates database for ALK+ patients determined 
by break-apart fluorescent in situ hybridization assay or EGFR 
mutation positive patients (exon 19 deletions or exon 21 
L858R mutations) determined either through direct sequenc-
ing or allele-specific polymerase chain reaction assays. An 
institutional review board approved protocol permits clinical 
correlates to be made on all patients seen at the University of 
Colorado in whom molecular analyses have been conducted 
within the Colorado Molecular Correlates laboratory.
Baseline clinical characteristics were determined by 
retrospective collection from electronic records, including 
age at diagnosis (taken at date of diagnostic biopsy), sex, 
tumor histology, prior therapy, method of CNS imaging 
before initiation with erlotinib or crizotinib, date of diagnosis 
of any known CNS involvement, treatment of any known CNS 
involvement before the initiation of erlotinib or crizotinib, 
smoking status, and sites of metastatic disease. If patients did 
not have imaging of the CNS within 3 months before com-
mencing TKI therapy and had no previous history of CNS 
metastases, they were assessed as having unknown CNS 
status. Smoking status was categorized as current (smoked 
within less than a year before start of therapy), former (quit 
more than a year before start of therapy), or never (less than a 
100 lifetime cigarettes).
All ALK+ patients received crizotinib (Xalkori, Pfizer, 
La Jolla, CA) starting at 250 mg twice a day on either the 
phase I expansion cohort of PROFILE 100138 or the nonran-
domized phase II PROFILE 1005 clinical trial,39 and received 
staging every 8 weeks (PROFILE 1001), or every 6 weeks 
(PROFILE 1005) with computer tomography (CT) or positron 
emission tomography (PET)/CT. Imaging of the brain at either 
baseline or on treatment in these trials was not mandatory 
for any patient but was performed at investigator discretion. 
All EGFR-MT patients received erlotinib (Tarceva, Astellas, 
Farmingdale, NY) starting at 150 mg once a day, with two of 
27 receiving erlotinib in combination with the insulin-like 
growth factor-1 receptor monoclonal antibody cixutumumab 
(Imclone, New York, NY) as part of a clinical trial.40,41
Baseline and ongoing CNS and body imaging with mag-
netic resonance imaging (MRI), CT and/or PET/CT for the 
25 of 27 EGFR-MT patients treated off study was performed 
according to investigator discretion. The two EGFR-mutated 
NSCLC patients treated with erlotinib and cixutumumab on 
trial had interval body CT scans performed every 6 weeks 
while on study, although both withdrew from study after 7 and 
8 months before progression to continue erlotinib alone, and 
had staging performed from this time according to investiga-
tor discretion. Median progression-free survival (PFS1) was 
calculated from time of initiation of targeted therapy to first 
progression of disease (as per Response Evaluation Criteria in 
Solid Tumors version 1.1 ) or clinical progression (as assessed 
by clinician), or death from any cause (using Kaplan–Meier 
methods). Sites of first progression (CNS or external to the 
CNS [eCNS]) were documented.
On the basis of institutional practice, patients who 
progressed on their oral targeted therapy who had either lep-
tomeningeal disease, more than four sites of eCNS progres-
sion, poor performance status (Eastern Cooperative Oncology 
Group >2) or poor tolerance of their targeted therapy were not 
considered suitable for LAT (n=26). A subset of patients with 
progression after initial treatment with either crizotinib or erlo-
tinib with either nonleptomeningeal CNS progression and/or 
less than 4 sites of eCNS progression, adequate performance 
status (Eastern Cooperative Oncology Group <2), and good 
tolerance of their targeted therapy (n = 25) were considered 
for LAT to the site(s) of progression and continuation of the 
same oral targeted therapy. Before LAT, patients underwent 
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a biopsy of the site of their progressive disease to determine 
the molecular mechanism of resistance to targeted therapy if 
this was determined to be safe by their treating oncologist and 
interventional radiologist which, in part, have been reported 
separately.16 Patients were instructed to withhold their oral 
targeted therapy on the days of local therapy with radiation 
and restart on the day after radiation was completed, with no 
change in dosage. Those patients who received surgical LAT 
were instructed to withhold the TKI until the surgical team 
considered it appropriate to recommence oral dosing.
The characteristics and timing of local ablative therapy 
(SBRT, standard radiation therapy [XRT], stereotactic radio-
surgery [SRS], whole brain radiation therapy [WBRT] or 
surgery), and number of disease sites treated was recorded. 
Electronic records of patients who received radiation or sur-
gery were reviewed for evidence of relevant systemic or local 
toxicity related to the volume irradiated for 6 months from 
the end of the LAT, including but not limited to fatigue and 
headaches after CNS irradiation; pneumonitis after lung irra-
diation; radiation-induced liver disease after liver irradiation; 
and skin toxicity after any SBRT or XRT. PFS2 was measured 
from the time of first progression until second progression on 
the same targeted therapy, using Response Evaluation Criteria 
in Solid Tumors 1.1 or death from any cause. Data analysis 
was performed up to January 1, 2012.
Statistical Analysis
Statistical analysis for creation of Kaplan–Meier curves 
was performed using Prism V software (Graphpad, San Diego, 
CA). Median survival time, confidence intervals, and a mul-
tivariate analysis with a Cox proportional hazards model was 
performed using version 9.3 of SAS/STAT software (SAS 
institute Inc., Cary, NC).
Results
Thirty-eight ALK+ patients received crizotinib, 28 (74%) 
of whom had progressed at the time of analysis. Twenty-seven 
EGFR-MT patients received erlotinib, 23 (85%) of whom had 
progressed at the time of analysis. Patient characteristics are 
summarized in Table 1. The majority of patients (63 of 65, 
97%) had adenocarcinoma histology, and the median age was 
58 years. Collectively, 19 of 65 patients (29%) had known 
CNS metastases before commencement with targeted therapy, 
but 29 of 65 patients (45%) with no history of CNS metasta-
ses did not have MRI or CT imaging of their brain performed 
in the 3 months before commencement on either drug. The 
median duration of follow-up was 20 months. The PFS1 of the 
65 NSCLC patients treated with either crizotinib or erlotinib 
was 10.3 months (9.0 months for ALK+ patients, 13.8 months 
for EGFR-MT patients [Table 1]).
Among 28 ALK+ patients who had progressed at the 
time of the analysis, 13 (46%) first progressed in the CNS at 
PFS1 (two of whom progressed simultaneously in the CNS 
and eCNS) and the CNS failure rate was similar in the 18 
ALK+ patients who had a documented CNS status (14 with 
CNS metastases, four with no CNS metastases) before com-
mencing crizotinib (seven of 18, 39%). Among EGFR-MT 
patients, five of 23 patients (22%) first progressed in the CNS 
at PFS1 (two simultaneously in CNS and eCNS), and again the 
CNS failure rate was similar in the subgroup of 10 EGFR-MT 
patients who had a documented CNS status (five with CNS 
metastases, five with no CNS metastases) before commencing 
erlotinib (two of 10, 20%).
Of the 28 ALK+ patients who had progressed, 15 of 28 
(54%) received LAT after first progression and were treated 
beyond progression with crizotinib. Of the 23 EGFR-MT 
patients who had progressed, 10 (43.5%) received LAT after 
TABLE 1.  Demographics of Patients
ALL PTS ALK+ EGFR-MT ALL PTS
TBP
ALK +
TBP
EGFR-MT
TBP
No. 65 38 27 25/51 (49%) 15/28 (54%) 10/23 (43%)
Age (median, yr) 58 55 60 58 50 59
Range 23–80 23–80 46–75 23–75 23–72 54–75
Female sex 37 (57%) 18 (47%) 19 (70%) 16 (64%) 8 (53%) 8 (80%)
Never smokers 43 (66%) 26 (68%) 17 (63%) 15 (60%) 11 (73%) 4 (40%)
Previous lines Rx
Mean 2.5 3 1.85 2.5 2.9 2.0
Range 0–6 1–6 1–4 0–4 1–4 0–2
CNS status pre C1
None 17 (26%) 10 (26%) 7 (26%) 5 (20%) 4 (27%) 1 (10%)
Present 19 (29%) 14 (37%) 5 (18%) 8 (32%) 5 (33%) 3 (30%)
Unknown 29 (45%) 14 (37%) 15 (56%) 12 (48%) 6 (40%) 6 (60%)
PFS1 (mo)
Median 10.3 9.0 13.8 9.8 9.0 12.0
95% CI 8.9–13.8 6.5–12.8 8.9–16.4 8.8–13.8 6.5–12.0 6.5–19.0
No events 51 28 23 25 15 10
PTS, patients; ALK +, ALK positive as defined by fluorescence in situ hybridization; TBP, treated beyond progression with local ablative therapy; CNS, central nervous system; 
CI, confidence interval; PFSI, median progression-free survival; EGFR-MT, EGFR-mutant.
1810 Copyright © 2012 by the International Association for the Study of Lung Cancer
Weickhardt et al. Journal of Thoracic Oncology  •  Volume 7, Number 12, December 2012
first progression and were treated beyond progression with 
erlotinib. Overall, 25 of 51 patients (49%) received LAT at 
first progression. All patients who received LAT recom-
menced their TKI after therapy. The median time from PFS1 
to the start of LAT was 3.7 weeks. The PFS1 was 9.8 months 
for all 25 patients with oligoprogressive disease, who received 
LAT and continuation of targeted therapy (9.0 months for 
ALK+ patients, 12.0 months for EGFR-MT patients). The 
PFS1 was 12.8 months for all patients with progression, who 
did not receive LAT and continuation of targeted therapy 
(7.2 months for ALK+ patients, 13.9 months for EGFR-MT 
patients Table 1).
The pattern of progression at PFS1 for those 25 patients 
treated with LAT for oligoprogressive disease is shown in 
Table 2. Seventeen of the 25 patients (68%) had restaging 
of their CNS with an MRI of the brain at the time of PFS1. 
Seventeen of the 25 patients (68%) had systemic restaging 
with PET/CT at the time of PFS1, with all others using CT 
scanning. Thirteen patients (nine ALK+, four EGFR-MT) 
first progressed in the CNS, with 10 of 13 patients (77%) only 
having progression in their CNS while still having control of 
systemic disease outside the CNS. All six patients with fewer 
than four CNS metastases were treated with SRS. A single 
patient with eight sites of cerebral metastases was treated 
with SRS to each site at an outside institution. Otherwise, 
all other patients with four or more CNS metastases received 
WBRT. The majority of the 15 patients who progressed out-
side the CNS and were treated with local therapy were treated 
with SBRT (15–54 Gy, median 40 Gy), with eight of 15 
(53%) having a single site of progression treated. Up to four 
eCNS sites were treated (median 2), with the most common 
sites being bone and lung. One patient underwent an adre-
nalectomy, and two patients were treated with XRT to bone 
metastases (either with 20 Gy in five fractions or 30 Gy in 10 
fractions).
For the 17 patients who received CNS restaging at 
PFS1, the median interval of CNS restaging between PFS1 
and PFS2 was 3.1 months. The median interval of systemic 
restaging between PFS1 and PFS2 was 2.1 months. The 
median follow-up post-LAT at the time of analysis was 9.4 
months. For the 25 patients who received LAT and continued 
on targeted therapy, the median PFS2 from the time of PFS1 
was 6.2 months (Table 3, Fig. 1). The median PFS2 in patients 
with initial CNS only progression was 7.1 months. Median 
PFS2 in patients with initial eCNS progression, including 
three patients who had CNS progression detected within a 
month of systemic progression, was 4.0 months. The pattern 
of progression at PFS2 is shown in Table 3. Of patients who 
progressed initially in the CNS, 50% next progressed outside 
the CNS. Similarly, of patients who progressed initially outside 
the CNS, 53% next progressed outside the CNS again. At the 
time of analysis, six of 25 patients (24%) had not progressed 
again after local therapy post-PFS1 after a median follow-up 
of 7 months. There was a trend for patients whose time to first 
progression was less than or equal to 12 months to have a 
shorter time to second progression, (hazard ratio=3.45, 95% 
confidence intervals 0.92–12.99, p = 0.067) but this was not 
statistically significant.
The majority of adverse events relating to ablative ther-
apy occurred in patients having WBRT. Radiation-induced 
liver damage was not observed in the patient who received 
liver SBRT. Grade 3 fatigue was reported in two patients 
within the 6 months after WBRT, but there were no other doc-
umented grade 3/4 adverse events attributable to radiotherapy 
(Table 4).
DISCUSSION
Oncologists have traditionally discontinued or changed 
systemic therapy when there is objective evidence of radio-
logical or clinical progression, intolerable toxicity, or com-
pletion of a fixed number of treatment cycles. However, in 
cases of progression on a previously beneficial targeted agent 
for molecularly subtyped cancer other options may exist. 
Specifically, our experience suggests that when patients 
with EGFR-MT or ALK+ NSCLC progress on erlotinib or 
crizotinib, respectively, and the progression occurs in only a 
limited number of sites (oligoprogressive disease) it may be 
reasonable to consider LAT to the sites of progression and 
TABLE 2.  Sites of Oligoprogression and LAT Treatment 
Modality
No. of PTS SRS WBRT SBRT XRT Surgery
CNS as site of first progression
Lesions < 4 6 6 — — —
Lesions > 4 7 1 6 — — —
eCNS as site of first progression
Bone 7 — — 5 2 —
Lung 7 — — 7 — —
Lymph node 2 — — 2 — —
Adrenal 2 — — 1 — 1
Liver 1 — — 1 — —
LAT, local ablative therapy; SRS, stereotactic radiosurgery; WBRT, whole brain 
radiation therapy; SBRT, stereotactic body radiation therapy; XRT, external beam 
radiotherapy; CNS, central nervous system of disease; eCNS, extra-CNS site of 
disease; PTS, patients.
TABLE 3.  Outcomes from LAT and Continuation of Targeted 
Therapy
Site of First 
Progression
No. of 
Patients
PFS1 (mo)
(CI)
PFS2 (mo)
(CI)
Site of Second 
Progression
CNS 10 10.9 7.1 2 (20%) No prog
7.3–18.3 1.7–11.3 3 (30%) CNS
5 (50%) eCNS
eCNSa 15 9.0 4.0 4 (27%) No prog
6.5–13.8 2.7–7.4 3 (20%) CNS
8 (53%) eCNS
All patients 25 9.8 6.2 6 (24%) No prog
8.8–13.8 3.7–8.0 7 (28%) CNS
12 (48%) eCNS
a Includes three patients who progressed eCNS and CNS at PFS1. 
CI, confidence interval; CNS, central nervous system as site of disease; eCNS, 
extra-CNS sites of disease; PFS1, median progression-free survival.
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continuation of the TKI (Table 5, Fig. 2). Forty-nine percent 
of patients treated with either erlotinib or crizotinib who pro-
gressed at our institution were deemed appropriate for this 
treatment strategy.
Patients treated with crizotinib or erlotinib in this series 
had a median PFS1 of 10.3 months, consistent with literature 
precedent.1–6 Although retrospective series of radiotherapy 
used in oligometastatic disease at diagnosis in metastatic 
NSCLC report good local control rates and better overall 
survival than in historical controls,42–48 there is little published 
data about the use of local therapy for oligoprogressive disease 
on therapy. This study suggests that in patients with EGFR-MT 
or ALK+ NSCLC on erlotinib or crizotinib therapy who 
develop either less than four systemic progressive lesions (the 
maximum treated in this series) and/or CNS progression, LAT 
(either radiation or surgery) and continuation of the TKI may 
extend disease control by over 6 months. Our results expand 
on recently published work on the role of LAT in patients with 
EGFR-MT. A Japanese group reported a median eCNS PFS2 
of 5.6 months after LAT of isolated CNS progression in 17 
NSCLC patients who had achieved at least stable disease for 
more than 6 months on an EGFR-TKI,21 and an American 
group reported a median PFS2 of 10 months in 18 NSCLC 
patients with EGFR-MT after LAT of isolated sites of eCNS 
progression.49
In our series, no patients receiving LAT had radiologi-
cal evidence of leptomeningeal disease, which is associated 
with poor outcomes, lack of clear effective therapy, and there-
fore unlikely to be suited to a local treatment approach.50 
Strikingly, nearly half (13 of 28, 46%) of all ALK+ patients 
FIGURE 1. A, PFS1 and PFS1+PFS2 
survival curves of all 25 patients 
treated with LAT. B, Ten patients 
treated with LAT who first pro-
gressed only in the CNS. C, Fifteen 
patients treated with LAT who first 
progressed in extra-CNS locations, 
including three patients with simul-
taneous CNS and eCNS progression. 
PFS1, median progression-free sur-
vival; PFS2, progression-free survival 
from the time of first  progression; 
LAT, local ablative therapy; CNS, 
central nervous system; eCNS, 
extra-CNS.
TABLE 4.  Potential Treatment-Related Toxicity within 6 
Months of Completing LAT
WBRT (n= 6)
Other Ablative  
Therapy (n = 19)
Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4
Alopecia 6 0 0 0
Fatigue 1 2 3 0
Memory impairment 3 0 0 0
Nausea 1 0 1 0
Anorexia 1 0 1 0
Emotional lability 2 0 0 0
Headaches 1 0 0 0
Chest-wall tenderness 0 0 1 0
LAT, local ablative therapy; WBRT, whole brain radiotherapy. 
TABLE 5.  Suggested Criteria for Considering Local Ablative 
Therapy of Oligoprogressive Disease and Treatment with a 
TKI beyond Progression Includea
1.  ALK positive or EGFR-mutant metastatic non–small-cell lung cancer
2.  Relevant TKI (e.g., crizotinib or erlotinib) is well tolerated
3.  Oligoprogressive disease on TKI therapy, defined as:
   CNS progression without leptomeningeal disease amenable to WBRT, 
SRS, or surgical resection.
   Progression in ≤ 4 extra-CNS sites amenable to SBRT, XRT, or surgical 
resection.
aBased on the practices within this study.
WBRT, whole brain radiation therapy; SRS, stereotactic radiosurgery; SBRT, 
stereotactic body radiation therapy; XRT, conventionally fractionated radiation therapy; 
TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor recepetor.
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progressed first in the CNS, with the majority (11 of 13) 85% 
still responding or with stable disease systemically, making 
a LAT approach combined with ongoing use of crizotinib 
particularly attractive within this group. In patients without 
baseline CNS imaging with documented CNS progression, it 
is not possible to categorically state whether new CNS lesions 
reflect true CNS progression or simply the new discovery of 
lesions that preexisted. However, the fact that the rates of 
CNS progression were very similar among those with known 
CNS status at baseline (39%), suggests that the predominant 
effect is one of true CNS progression. Failure in the CNS may 
be because of inadequate crizotinib exposures rather than a 
change in the dominant biology of the tumor.10,51–53 Similar 
data relating to the potential for the CNS to represent a rela-
tive sanctuary site with respect to EGFR-TKI therapy for 
EGFR-MT disease also exist.10 In contrast, systemic mech-
anisms of resistance to these drugs relate to several differ-
ent biological changes in the tumor, such as kinase domain 
mutations in the target enzyme or the development of addi-
tional oncogenic drivers.13,15,54–56 It is uncertain whether the 
potential for there to be different explanations for failure in 
CNS and systemic sites accounts for a trend toward improved 
PFS2 in patients receiving LAT for isolated CNS progres-
sion at PFS1 relative to those patients receiving LAT for sys-
temic progression. In our series, patients with isolated CNS 
progression had a median time to next progression of over 7 
months, as compared with a PFS2 of 4.0 months in patients 
who experienced first progression outside the CNS; however, 
this difference was not statistically significant (hazard ratio 
for progression 0.85, 95% confidence interval 0.29–2.47, 
p = 0.76).
There are several limitations of this study. Safety data 
on radiation-related side effects within this study were col-
lected and graded retrospectively. However, the safety of com-
bining aggressive, ablative-intent SRS or SBRT regiments 
with TKI- or monoclonal antibody-based EGFR inhibition 
has been reported for both CNS and extracranial sites, so 
the apparent good tolerability of our approach would not be 
unexpected.57–60
There was a lack of standardized timing interval in 
systemic restaging patients taking erlotinib although not on 
clinical trial, and no standardized timing of CNS staging in 
either the crizotinib or erlotinib group. The median interval 
of restaging between PFS1 and PFS2 was 3.1 months for 
CNS in those with restaging MRI at PFS1, and 2.1 months 
for eCNS sites of disease, which is less than half the time 
interval of the additional apparent disease control from LAT. 
On the basis of institutional precedent, we limited the number 
of eCNS lesions considered for LAT to four or fewer sites, 
and in most cases the number of CNS lesions considered for 
SRS as opposed to WBRT to less than four. Emerging data 
suggest that SRS alone might be appropriate for a higher 
number of brain metastases as long as the total burden of 
tumor is limited,61 and there would be an opportunity to 
avoid the neurocognitive toxicity associated with WBRT.62 
Similarly, whether the treatment of symptomatic and 
asymptomatic CNS metastases is equally beneficial to 
the patient remains unknown. All patients who received 
LAT continued to receive their TKI post-LAT, therefore, 
although we can comment on the outcomes associated with 
the combined approach, we cannot distinguish the specific 
contribution of each element.
Perhaps most importantly, we do not have a comparator 
group to judge the true benefit of our LAT/TKI continuation 
approach. Historical controls of other chemotherapies in 
NSCLC cannot accurately be used given that this was a 
retrospective review of a molecularly defined population, 
treated across several different lines of therapy. Of note, as 
the PFS1 in the LAT-treated group and the non-LAT–treated 
group were comparable (10.3 versus 12.8 months), we do not 
seem to have preselected a more indolent population for LAT 
within this study. Although we have estimated the time to the 
next progression event in the LAT-treated group, additional 
LAT at the time of second progression was considered in 
several cases when only further oligoprogressive disease was 
manifested (data not shown). Consequently, in any prospective 
evaluation, comparing this approach, for example, to some 
standard chemotherapy in a defined line of treatment, both the 
clear delineation of the criteria for considering the initial and 
any repeat LAT acceptable and an assessment of the benefit of 
the approach on overall survival and quality of life and not just 
the PFS before the next intervention may be most informative. 
Within this study, at the time of analysis only four of 25 of the 
LAT group and 10 of 26 of the non-LAT–treated progressive 
group had died and therefore overall survival data are not 
mature.
FIGURE 2.  Proposed schema for incorporating local ablative therapy into therapy at time of first progression with ALK+ or 
EGFR-MT NSCLC patients treated with TKI therapy. ALK+, anaplastic lymphoma kinase gene rearrangement; EGFR-MT NSCLC, 
epidermal growth factor receptor-mutant non–small-cell lung cancer; TKI, tyrosine kinase inhibitors.
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Despite these limitations, this study provides rationale 
for considering the approach of LAT and continuation of a rel-
evant well-tolerated TKI in the treatment of oligoprogressive 
EGFR-MT and ALK+ NSCLC as an alternative to switch-
ing systemic therapy (Table 5, Fig. 2). However, we would 
strongly advocate that to delineate the true extent of benefit, 
a prospective clinical trial is required across multiple centers 
with defined treatment criteria and standardized restaging 
technology (PET/MRI) should be used at defined intervals to 
minimize bias.
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